BUSINESSJun 8 · 10:16 UTCMARKETWATCHSteve Goldstein

Eli Lilly stock jumps after late-stage trial of next-generation weight-loss drug

Eli Lilly shares jumped in premarket trade after a late-stage trial of its next-generation weight-loss drug impressed analysts.

Nexus surfaces and summarizes. The full story lives at the source.

Mentioned

Eli Lillyorganizationnext-generation weight-loss drugtopicanalyststopic

Spot something wrong with this article?Report a problem →

Forward this

Related Signal

Adjacent reporting

BUSINESSJan 24 · 16:52 UTC
Novo Nordisk Shares Surge on New Obesity Drug Results
BUSINESSApr 17 · 17:41 UTC
Obesity Firm Kailera Therapeutics Up 63% After $625 Million IPO
BUSINESSMay 22 · 11:08 UTC
Estée Lauder surges in premarket after Puig merger deal talks end
BUSINESSJun 8 · 09:40 UTC
Weight loss drug maker sinks 25% after new safety data spooks investors
HEALTHJun 2 · 07:43 UTC
Biotech takeover target Abivax sinks over 30% after bowel disease drug trial update
BUSINESSJun 3 · 13:36 UTC
STAT+: Legend Biotech emerged as a rare market winner